Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Earnings Release 2021

Nov 27, 2020

3535_rns_2020-11-27_dad9988d-3385-48f6-9a65-d77247a826f5.html

Earnings Release

Open in viewer

Opens in your device viewer

Aqua Bio Technology ASA: Safety studies by Nordic Beauty completed and approved

Aqua Bio Technology ASA: Safety studies by Nordic Beauty completed and approved

This information is subject to the disclosure requirements pursuant to Section

5-12 the Norwegian Securities Trading Act

Update on product series from DCP

We refer to the stock exchange announcement of 26 November 2020 regarding safety

studies for the Nordic Beauty and Balance & Vitality product series. We have

today received confirmation from Eurofins (https://www.eurofins.com/about-us/ )

that Nordic Beauty has passed all the safety studies that the EU requires to be

carried out before commercialization. The tests were performed at Eurofins,

which is the world's largest in testing food, environment, medicine and

cosmetics and has 800 laboratories in more than 50 different countries.

As mentioned in the stock exchange announcement of 26 November 2020, this means

that ABT expects the Nordic Beauty product series to be ready for distribution

and sale in the first half of 2021.

For further information, please contact Espen Kvale, CEO, telephone

+47 916 28 092 - [email protected]. Aqua Bio Technology (ABT) is

developing and commercializing sustainable biotechnology for use in skin care

products. ABT's cosmetics ingredients are effective and they provide the

cosmetics industry with natural alternatives to traditional ingredients. ABT is

also marketing and distributing natural skin care products developed by partners

towards consumers and professional users.  ABT's focus on commercialization and

development of natural ingredients and natural skin care products has been, and

will continue to be, an important part of the company's strategy going forward.

Aqua Bio Technology is listed on the Axess market of the Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.